A single‐centre, prospective cohort study of COVID‐19 patients admitted to ICU for mechanical ventilatory support

• DOI: 10.1111/aas.13726
• Publication Date: 2020-10-31T16:39:47Z
• Authors: Signe Søvik; Per M. Bådstøløkken; Vibecke Sørensen; Peder Langeland M...; Christian Prebensen; Torbjørn Omland; Jan‐Erik Berdal
• Keywords: Dalteparin; Male; Critical Care; 610; Time; Cohort Studies; Fibrin Fibrinogen Degradation Products; Tertiary Care Centers; 03 medical and health sciences; 0302 clinical medicine; Humans; Prospective Studies; Lung; Inpatients; SARS-CoV-2; Intensive Care and Physiology; Anticoagulants; COVID-19; General Medicine; Middle Aged; Respiration, Artificial; COVID-19 Drug Treatment; 3. Good health; Intensive Care Units; Anesthesiology and Pain Medicine; Treatment Outcome; Female

BackgroundMortality rates in COVID‐19 patients in need of mechanical ventilation are high, with wide variations between countries. Most studies were retrospective, and results may not be generalizable due to differences in demographics, healthcare organization and surge capacity. We present a cohort of mechanically ventilated COVID‐19 patients from a resource‐rich, publicly financed healthcare system.MethodsProspective study from a tertiary hospital. Consecutive SARS‐CoV‐2 positive adult patients admitted to the ICU for mechanical ventilation from 10 March 2020 to 04 May 2020 were included. Triage and treatment were protocolized. High‐dose dalteparin was adjusted by D‐dimer. Demographics, treatments and high‐resolution physiological variables were collected. Outcomes were 30‐day and hospital mortality. Data are medians (quartiles).ResultsOf the 1484 persons in the hospital catchment area testing positive for SARS‐CoV‐2, 201 (13.5%) were hospitalized. Thirty‐eight (19%) patients were mechanically ventilated, of whom five (13%) died. Of the 163 patients treated with supplemental oxygen, eight (5%) died.In ventilated patients (75% males, age 61 (53‐70) years), severe, moderate and mild ARDS was present in 25%, 70% and 5%. Tidal volume ≤8 mL/kg ideal bodyweight was achieved in 34 (94%) patients. Proning and neuromuscular blockers were used in 19 (54%) and 20 (61%) patients. Duration of ventilation was 12 days (8‐23). D‐dimer peaked at 3.8 mg/L (2.1‐5.3), and maximum dalteparin dose was 15 000 IU/24 h (10 000‐15 000). Despite organizational changes, a high degree of adherence to treatment protocols was achieved.ConclusionIn a prospective cohort study of mechanically ventilated COVID‐19 patients treated in a resource‐rich, publicly financed healthcare system, mortality was considerably lower than previously reported in retrospective studies.